ENEA Tech Video

BetaGlue Therapeutics and its shareholders are proud to collaborate with Fondazione Policlinico Universitario Agostino Gemelli in the fight against cancer. Our clinical study in locally advanced pancreatic cancer is on-going. Learn more with this video.

Coming soon

Events

See what BetaGlue will attend
MioLive - Roma

World Congress of Interventional Oncology

MIOLive

January 26-27, 2026 | Rome

Register interest: info@betaglue.com


Gianluca
De Danieli
Head of Clinical Development
Spectrum Miami

Advancements in the fight against cancer

Spectrum Conference

January 15-17, 2026 | Miami (FL), USA

Register interest: info@betaglue.com


Alexis
Peyroles
CEO
Salvatore
Calabrese
CFO
Gianluca
De Danieli
Head of Clinical Development
San Francisco - JP Morgan Health Conference

44th Annual J.P. Morgan

Healthcare Conference

January 12-15, 2026 | San Francisco, California

Register interest: info@betaglue.com


Alexis
Peyroles
CEO
Salvatore
Calabrese
CFO
Gianluca
De Danieli
Head of Clinical Development

What we’re building

News

Discover the latest from our lab and clinic
ENEA-Tech Biomedical Foundation Invests €6m in BetaGlue® Therapeutics Bringing 2024 Funding Round Total to €24m
ENEA TECH - BIO MEDICAL

ENEA-Tech Biomedical Foundation Invests €6m in BetaGlue® Therapeutics Bringing 2024 Funding Round Total to €24m

Milan, December 16th 2024 - BetaGlue® Therapeutics S.p.A. (“BetaGlue”) an Italian clinical-stage oncology company developing an innovative radiotherapy platform for the targeted and personalised treatment of unresectable solid tumours, called…

Read more
1201 801 Betaglue® Therapeutics
BetaGlue® Adds €8m Equity Financing to €10m EIC Accelerator Award
Colin Story - BetaGlue

BetaGlue® Adds €8m Equity Financing to €10m EIC Accelerator Award

Milan, June 6, 2024 – BetaGlue® Therapeutics (“BetaGlue” or the “Company”) a clinical-stage radiotherapy company developing novel products for the personalised treatment of solid tumour cancers today announces the closing…

Read more
1201 801 Betaglue® Therapeutics
BetaGlue® Therapeutics Announces the Appointment of Mike Cogswell as Chairman and Mike Maszy as Non-Executive Director
New Betaglue board members

BetaGlue® Therapeutics Announces the Appointment of Mike Cogswell as Chairman and Mike Maszy as Non-Executive Director

Milan, May 15, 2024 – BetaGlue® Therapeutics (“BetaGlue” or the “Company”) a clinical-stage company developing novel radiotherapy products for the personalised treatment of solid tumour cancers today announces the appointment…

Read more
1200 800 Betaglue® Therapeutics